Go Back To Menu
Close
- Mailing Form
-
Medical Report*
-
Go Back To Menu
Chondrosarcoma is a malignant bone tumor originating in cartilage tissue, mainly occurring in long bones such as the femur, humerus, and pelvic region. It is relatively rare but highly malignant. It is characterized by slow growth with local destructiveness, and some subtypes have the potential for distant metastasis. The disease is more common among middle-aged and elderly populations, especially men over 50. Certain subtypes, such as mesenchymal chondrosarcoma, may also affect adolescents. At diagnosis, tumors are often already large, requiring multidisciplinary intervention with surgery, radiotherapy, chemotherapy, and cell therapy to achieve better therapeutic outcomes.
Chondrosarcoma has a relatively low global incidence, accounting for about 20% of all osteosarcomas. In developed countries such as the U.S. and Germany, the diagnostic rate is higher due to widespread imaging examinations, allowing earlier detection. In Asian regions such as China and India, the number of diagnosed cases has been rising in recent years with increased medical awareness.
1. Bone structure destruction
Chondrosarcoma often occurs in weight-bearing bones. Once the tumor erodes normal bone tissue, it leads to local fractures or joint deformities. Patients usually experience persistent pain and limited limb mobility, severely affecting quality of life.
2. Nerve and vascular compression
As the tumor grows, it often compresses surrounding nerves and blood vessels, causing numbness, swelling, and poor blood circulation. In severe cases, this may result in motor dysfunction and functional loss.
3. Malignant metastasis risk
Some subtypes of chondrosarcoma, especially dedifferentiated types, have the potential for distant metastasis. The lungs are the most common metastatic site, and once metastasis occurs, treatment becomes much more difficult, directly affecting prognosis.
4. Psychological and social impact
Chondrosarcoma often requires surgical bone resection or amputation. Patients suffer not only physical trauma but also psychological stress from changes in appearance and loss of function, requiring psychological support and rehabilitation guidance.
Immune reconstruction cell therapy activates the patient’s immune system to target and clear tumor cells while repairing immune functions damaged by radiotherapy, chemotherapy, or surgery. It is characterized by strong systemic action and low toxicity, suitable for postoperative consolidation and controlling metastasis risk, making it an emerging force in comprehensive chondrosarcoma treatment.
During traditional treatments such as surgery, radiotherapy, and chemotherapy, patients with tumors often face immune dysfunction, increased infection risk, and slow recovery. To help patients better sustain treatment, improve tolerance, and enhance quality of life, scientifically phased immune reconstruction plans tailored to different treatment cycles are required.
● Short-term plan: Rapidly enhance immunity through immune cell reinfusion, boosting the effectiveness of anti-tumor treatment.
● Mid-term plan: Reduce the side effects of traditional treatments, promote physical recovery, and complete standardized treatment courses.
● Long-term plan: Improve overall immunity through immune cell reconstruction, gut immune reconstruction, elemental immune reconstruction, and immune nutrition reconstruction, thereby enhancing quality of life and prolonging survival.
1. Surgical resection
For localized chondrosarcoma, surgical resection remains the first-line treatment. Depending on tumor size and location, wide excision, function-preserving surgery, or amputation may be selected. Advances in modern surgical techniques have made limb-preserving surgery a feasible option for more patients.
2. Radiotherapy
For patients at high surgical risk or with residual tumors after incomplete resection, radiotherapy may be used to control local progression. It is particularly useful for non-surgical candidates or postoperative recurrence, though bone tissue tolerance to radiation must be considered.
3. Targeted drug therapy
For specific chondrosarcoma subtypes, such as cases related to IDH1 or IDH2 mutations, targeted drugs are already in clinical trials. In the future, targeted therapy may be combined with conventional therapies to form a more precise individualized treatment model.
4. Minimally invasive adjuvant therapy
In preoperative or local control, some centers are exploring minimally invasive approaches such as radiofrequency ablation and cryotherapy for small tumors or metastases. These methods cause minimal trauma, allow quick recovery, and are suitable for patients intolerant to surgery or as adjuvant control for recurrence.
5. Chemotherapy assistance
Chondrosarcoma generally responds poorly to traditional chemotherapy, but for high-risk subtypes such as dedifferentiated cases, pre- or postoperative combination chemotherapy can delay recurrence and control micrometastases. Suitable regimens should be selected based on pathology and patient condition.
Chondrosarcoma is characterized by certain malignant features, often asymptomatic in the early stage and diagnosed only after invading surrounding structures. Experts at United Life International Medical Center emphasize that surgery combined with immune reconstruction cell therapy, minimally invasive interventions, and precise individualized treatment are key to extending survival and preserving function. Active treatment can effectively improve quality of life and long-term prognosis.
